Use of mesenchymal stem cell therapy in COVID-19 related strokes  

作　　者：Mahika Rawat Chiao Ng Emaad Khan Rayyan A.Shah Suha Ashfaq Ghaith A.Bahader Zahoor A.Shah 

机构地区：[1]Department of Medicinal and Biological Chemistry,College of Pharmacy and Pharmaceutical Sciences,University of Toledo,Toledo,OH,USA

出　　处：《Neural Regeneration Research》2023年第9期1881-1883,共3页中国神经再生研究（英文版）

摘　　要：Co ronavirus disease 2019(COVID-19) has affected a broad demographics,eliciting a more significant effect on specific groups such as males,African Americans,and Hispanic minorities.Treatment of COVID-19 often requires antiviral drugs or monoclonal antibodies.However,immunotherapies such as mesenchymal stem cells and mesenchymal stem cells-derived exosomal vesicles should be evaluated as treatment options for COVID-19.Mesenchymal stem cell thera py offe rs regenerative,anti-inflammatory,and immunomodulato ry properties that can speed up the recovery from COVID-19.Mesenchymal stem cell therapy can also benefit COVID-19 patients who suffer from stro kes,as COVID-19 increases the risk of strokes due to increased cytokines and clotting facto rs.Most stroke cases that occur in COVID-19 patients are ischemic strokes.Therefo re,with the help of mesenchymal stem cell therapy and mesenchymal stem cells-derived exosomes,COVID-19-induced stroke patients might benefit from dual-ended treatment.The o bjective of this review was to discuss COVID-19 and stroke incidence and the available treatment options.

关 键 词：COVID-19 CYTOKINES IMMUNOTHERAPY INTERLEUKIN-7 mesenchymal stem cells NEUROINFLAMMATION sex differences stroke 

分 类 号：R563.1[医药卫生—呼吸系统]